FDA Approves a Highly Questionable New Diabetes Drug, Invokana
The FDA just gave its approval to the first drug in a new class of diabetes drugs, Johnson & Johnson's canagliflozin, which will be marketed in the U.S. as Invokana.New York Times: FDA Approves a New Diabetes Drug From J.&J. (May require subscription)Reuters: U.S. FDA approves Johnson & Johnson diabetes drug, canagliflozinThis class of drugs, the sodium-glucose co-transporter-2 (SGLT2) inhibitors, lowers blood sugar by blocking reabsorption of glucose by the kidney and increasing its excretion in urine. The manufacturer also claims that it causes weight loss--always a potent selling point for a diabetes drug.As...
Source: Diabetes Update - March 31, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Public Citizen target canagliflozin
FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee
Canagliflozin, Part of a New Class of Diabetes Drugs, Presents Too Many Risks to Patients
WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the diabetes drug canagliflozin because it could significantly harm patients and does not present significant benefit over current medications, Public Citizen said today.
In testimony today before an FDA advisory committee, director of Public Citizen’s Health Research Group Dr. Sidney Wolfe warned that the new drug presents an unsafe increase of risk for low b...
Source: PharmaGossip - January 10, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
